<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110601</url>
  </required_header>
  <id_info>
    <org_study_id>SGEN-2017PM1</org_study_id>
    <nct_id>NCT03110601</nct_id>
  </id_info>
  <brief_title>Study of PM Modulation Therapy in Trial Phase</brief_title>
  <official_title>Trialing of PM Modulation Therapy in Patients With Chronic Intractable Low Back Pain With or Without Leg Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stimgenics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stimgenics LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trialing of PM modulation therapy in patients with chronic intractable low back pain
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Actual">October 12, 2017</completion_date>
  <primary_completion_date type="Actual">October 12, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Relative to Baseline and After a Trial Period</measure>
    <time_frame>Baseline and 4 days plus or minus 1 days</time_frame>
    <description>Numerical rating pain score measured before and after intervention. 11-point Numeric Pain Rating Scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable (1-3 is rated as mild pain, 4-6 is rated at moderate pain, 7-9 is rated as severe pain). Subject rates average pain for the past 7 days.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Control - Conventional SCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Washout Period</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>1 day where no stimulation is provided</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test - Stimgenics SCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control - Conventional SCS</intervention_name>
    <description>Conventional SCS Parameters</description>
    <arm_group_label>Control - Conventional SCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test - Stimgenics SCS</intervention_name>
    <description>Stimgenics SCS Parameters</description>
    <arm_group_label>Test - Stimgenics SCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capable of giving written informed consent to participate in this clinical study based
             on voluntary agreement after a thorough explanation of the patient's participation is
             provided to them.

          2. Chronic intractable pain of the lower back equal to or greater than pain in lower
             limbs, and that has been refractory to conservative therapy for ≥ 3 months.

          3. Must be older than 18 years old.

          4. Average back pain intensity of ≥ 5 out of 10 on the numerical pain rating scale
             (NPRS).

          5. Appropriate candidate for spinal cord stimulation trial.

          6. Subjects must be on a stable dose of pain medication regimen for at least 1 month.

          7. Female patients who are not pregnant and do not plan to become pregnant during the
             study. Females of child bearing potential must provide a negative pregnancy test and
             must be using reliable contraception and must continue to use reliable contraception
             until study completion. Non-childbearing potential is defined as postmenopausal for at
             least 2 years or surgical sterilization or hysterectomy at least 3 months before study
             start. Patients who become pregnant or who have a spouse/significant other that
             becomes pregnant during the course of this study agree to report pregnancy to the
             study physician/staff.

          8. Must be able to comply with the requirement of study visits and follow-up and phone
             visits.

          9. Have cognitive ability of operate the remote control and follow therapy instructions
             and directions by clinicians.

        Exclusion Criteria:

          1. Systemic infection.

          2. Any active implanted device.

          3. Previous experience with SCS therapy either during a trial or fully implanted

          4. Evidence of serious neurological, psychological or psychiatric disorders.

          5. Mechanical spinal instability.

          6. Patients with uncorrected coagulation disorders or who are on anticoagulation therapy
             and cannot interrupt the therapy.

          7. Patient who are pregnant, breast-feeding or women of childbearing potential with
             positive pregnancy tests.

          8. Human immunodeficiency virus (HIV) infection or a clinically significant infection.

          9. Patients who are undergoing or will undergo therapies or diagnostics that involve
             electromagnetic fields such as: diathermy based therapies, electrocautery, magnetic
             resonance imaging (MRI), radiofrequency (RF) or microwave ablation, bone growth
             stimulators, electrolysis, therapeutic ultrasound, ultrasound, lithotripsy,
             psychotherapeutic procedures, radiation therapy, and transcutaneous electrical nerve
             stimulation.

         10. A clinically significant disorder such as cerebrovascular disease, pulmonary
             infarction, ischemic heart disease, cardiac dysrhythmia, myocardial infarction, or
             congestive heart failure or any other as determined by the investigator.

         11. Uncontrolled diabetes, uncontrolled pulmonary disease, or uncontrolled hypertension.

         12. Patients who have evidence of major psychiatric disease, mental disorder, drug
             dependency, alcohol dependency, or substance abuse disorders.

         13. Patients who have progressive neurological disease such as multiple sclerosis, chronic
             inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, acute
             herniated disc, or any other as determined by investigator.

         14. Medical condition or pain in other body areas that could interfere with study
             procedures, accurate pain reporting, and/or confound evaluation of study end points.

         15. Concurrent participation in another clinical study.

         16. Involvement in an injury claim under current litigation or a pending or approved
             workers' compensation claim.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>StimGenics</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <results_first_submitted>October 12, 2018</results_first_submitted>
  <results_first_submitted_qc>April 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03110601/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Non-randomized cross-over study in which all eligible participants received the same order of procedures (i.e. Conventional SCS parameters for 4 days, then a washout period of 1 day, then PM-SCS parameters for 4 days).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Arm With Multiple Periods</title>
          <description>Non-randomized cross-over study in which all eligible participants received the same order of procedures (i.e. Conventional SCS parameters for 4 days, then a washout period of 1 day, then PM-SCS parameters for 4 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Conventional SCS Parameters</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stimgenics SCS Parameters</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Chronic Back Pain Patients</population>
      <group_list>
        <group group_id="B1">
          <title>Enrolled Patients</title>
          <description>Back pain patients that were trialed with Conventional SCS parameters, then after a washout period the same patients were trialed with PM-SCS parameters (Stimgenics SCS parameters).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Back Pain on Numeric Pain Rating Scale (11-point rating scale)</title>
          <description>11-point Numeric Pain Rating Scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable (1-3 is rated as mild pain, 4-6 is rated at moderate pain, 7-9 is rated as severe pain). Subject rates average back pain for the past 7 days.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leg Pain Numeric Pain Rating Scale (11-point rating scale)</title>
          <description>11-point Numeric Pain Rating Scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable (1-3 is rated as mild pain, 4-6 is rated at moderate pain, 7-9 is rated as severe pain). Subject rates average leg pain for the past 7 days.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Relative to Baseline and After a Trial Period</title>
        <description>Numerical rating pain score measured before and after intervention. 11-point Numeric Pain Rating Scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable (1-3 is rated as mild pain, 4-6 is rated at moderate pain, 7-9 is rated as severe pain). Subject rates average pain for the past 7 days.</description>
        <time_frame>Baseline and 4 days plus or minus 1 days</time_frame>
        <population>Chronic Back Pain Patients with or without leg pain; 4 subjects experience known adverse events (such as lead migration) that prevented them from testing Stimgenics SCS.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional SCS</title>
            <description>Mean Back Pain Score after treatment Conventional SCS parameters</description>
          </group>
          <group group_id="O2">
            <title>Stimgenics SCS</title>
            <description>Mean Back Pain Score after treatments with Stimgenics SCS parameters</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Relative to Baseline and After a Trial Period</title>
          <description>Numerical rating pain score measured before and after intervention. 11-point Numeric Pain Rating Scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable (1-3 is rated as mild pain, 4-6 is rated at moderate pain, 7-9 is rated as severe pain). Subject rates average pain for the past 7 days.</description>
          <population>Chronic Back Pain Patients with or without leg pain; 4 subjects experience known adverse events (such as lead migration) that prevented them from testing Stimgenics SCS.</population>
          <units>Score on a 11 point scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.0"/>
                    <measurement group_id="O2" value="2.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1-10 days</time_frame>
      <desc>Same as clinicaltrials.gov definition</desc>
      <group_list>
        <group group_id="E1">
          <title>Conventional SCS</title>
          <description>Conventional SCS parameters for 4 days</description>
        </group>
        <group group_id="E2">
          <title>Washout Period</title>
          <description>Washout period of 1 day</description>
        </group>
        <group group_id="E3">
          <title>Stimgenics SCS</title>
          <description>Stimgenics SCS parameters for 4 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epidural abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Lead movement</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Patients were evaluated during the trial phase.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>VP of Clinical Affairs</name_or_title>
      <organization>Stimgenics</organization>
      <phone>309-662-4321 ext 217</phone>
      <email>clinicalSG@stimgenics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

